Rupp AC, Tomlinson AJ, Affinati AH, Yacawych WT, Duensing AM, True C, et al
Prioritise protein to protect muscle Research suggests that people losing weight on GLP-1 receptor agonists often fall well short of recommended protein targets, which can accelerate muscle loss
Meanwhile these agents have the potential to reduce major adverse cardiovascular events (MACE) in patient with T2DM as a drug class, individual drugs have different potency and effects they need tailored approach to align with patient treatment goals rather than generalized use (117)
Science 281 , 703706 (1998)
Years of post-marketing surveillance for Ozempic (diabetes) and Wegovy (obesity) have generated a robust safety profile that tirzepatide, as a newer molecule, is still building